In a filing, Akero Therapeutics Inc revealed its Director Graham G. Walmsley acquired Company’s shares for reported $4.09 million on Mar 25 ’25. In the deal valued at $44.75 per share,91,309 shares were bought. As a result of this transaction, Graham G. Walmsley now holds 1,091,309 shares worth roughly $46.62 million.
Then, Graham G. Walmsley bought 58,691 shares, generating $2,524,417 in total proceeds. Upon buying the shares at $43.01, the Director now owns 1,150,000 shares.
Before that, Graham G. Walmsley bought 50,000 shares. Akero Therapeutics Inc shares valued at $2,177,700 were divested by the Director at a price of $43.55 per share. As a result of the transaction, Graham G. Walmsley now holds 1,200,000 shares, worth roughly $51.26 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Friday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -1.97% to $42.72. Over the last five days, the stock has lost -5.53%. Akero Therapeutics Inc shares have risen nearly 53.56% since the year began. Nevertheless, the stocks have risen 75.15% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $45.49, while 200 days put it at $32.07.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 41.53, which if violated will result in even more drops to 40.33. On the upside, there is a resistance level at 44.65. A further resistance level may holdings at 46.57. The Relative Strength Index (RSI) on the 14-day chart is 42.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.82%. Stochastics %K at 32.29% indicates the stock is a holding.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-03-14, growing by 0.42 million shares to a total of 5.2 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.79 million shares. There was a rise of 8.03%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
